Advertisement

Psychiatric Disorders as Vulnerability Factors for Nicotine Addiction: What Have We Learned from Animal Models?

Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 24)

Abstract

Epidemiological studies indicate a high prevalence of tobacco smoking in subjects with psychiatric disorders. Notably, there is a high prevalence of smoking among those with dependence to other substances, schizophrenia, mood, or anxiety disorders. It has been difficult to understand how these phenomena interact with clinical populations as it is unclear what preceded what in most of the studies. These comorbidities may be best understood by using experimental approaches in well-controlled conditions. Notably, animal models represent advantageous approaches as the parameters under study can be controlled perfectly. This review will focus on evidence collected so far exploring how behavioral effects of nicotine are modified in animal models of psychiatric conditions. Notably, we will focus on behavioral responses induced by nicotine that are relevant for its addictive potential. Despite the clinical relevance and frequency of the comorbidity between psychiatric issues and tobacco smoking, very few studies have been done to explore this issue in animals. The available data suggest that the behavioral and reinforcing effects of nicotine are enhanced in animal models of these comorbidities, although much more experimental work would be required to provide certainty in this domain.

Keywords

Nicotine Schizophrenia Mood disorders Addiction Anxiety 

Notes

Acknowledgments

Funding Dr. Le Foll’s research is supported by CAMH, the Campbell Family Mental Health Research Institute, CIHR and the National Institute on Drug Abuse at the National Institutes of Health (1R21DA033515-01).

References

  1. Acri JB, Brown KJ, Saah MI, Grunberg NE (1995) Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacol Biochem Behav 50:191–198PubMedCrossRefGoogle Scholar
  2. Agrawal A, Budney AJ, Lynskey MT (2012) The co-occurring use and misuse of cannabis and tobacco: a review. Addiction 107:1221–1233PubMedCentralPubMedCrossRefGoogle Scholar
  3. Andreasen JT, Redrobe JP (2009a) Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 20:286–295PubMedCrossRefGoogle Scholar
  4. Andreasen JT, Redrobe JP (2009b) Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behav Brain Res 197:150–156PubMedCrossRefGoogle Scholar
  5. Andreasen JT, Olsen GM, Wiborg O, Redrobe JP (2009) Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 23:797–804PubMedCrossRefGoogle Scholar
  6. Andreasen JT, Henningsen K, Bate S, Christiansen S, Wiborg O (2011) Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline. J Psychopharmacol 25:1134–1141PubMedCrossRefGoogle Scholar
  7. Balerio GN, Aso E, Maldonado R (2005) Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 181:260–269PubMedCrossRefGoogle Scholar
  8. Balerio GN, Aso E, Maldonado R (2006) Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 184:504–513PubMedCrossRefGoogle Scholar
  9. Balsevich G, Poon A, Goldowitz D, Wilking Ja (2014) The effects of pre- and post-natal nicotine exposure and genetic background on the striatum and behavioral phenotypes in the mouse. Behav Brain Res 266:7–18PubMedCrossRefGoogle Scholar
  10. Battjes RJ (1988) Smoking as an issue in alcohol and drug abuse treatment. Addict Behav 13:225–230PubMedCrossRefGoogle Scholar
  11. Berg SA, Chambers RA (2008) Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropharmacology 54:1201–1207PubMedCentralPubMedCrossRefGoogle Scholar
  12. Berg SA, Sentir AM, Cooley BS, Engleman EA, Chambers RA (2014) Nicotine is more addictive, not more cognitively therapeutic in a neurodevelopmental model of schizophrenia produced by neonatal ventral hippocampal lesions. Addict Biol 19:1020–1031Google Scholar
  13. Besson M, David V, Baudonnat M, Cazala P, Guilloux JP, Reperant C, Cloez-Tayarani I, Changeux JP, Gardier AM, Granon S (2012) Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology 220:1–14PubMedCrossRefGoogle Scholar
  14. Bhattacharya SK, Chakrabarti A, Sandler M, Glover V (1995) Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety. Neurosci Lett 199:103–106PubMedCrossRefGoogle Scholar
  15. Biala G, Kruk M (2009) Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. J Pharm Pharmacol 61:493–502PubMedCrossRefGoogle Scholar
  16. Biala G, Kruk M, Budzynska B (2009) Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. J Physiol Pharmacol 60:113–122PubMedGoogle Scholar
  17. Braun Aa, Skelton MR, Vorhees CV, Williams MT (2011) Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav 97:406–415PubMedCentralPubMedCrossRefGoogle Scholar
  18. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE (1997) Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54:71–80PubMedCrossRefGoogle Scholar
  19. Brown RW, Maple AM, Perna MK, Sheppard AB, Cope ZA, Kostrzewa RM (2012) Schizophrenia and substance abuse comorbidity: nicotine addiction and the neonatal quinpirole model. Dev Neurosci 34:140–151PubMedCrossRefGoogle Scholar
  20. Cope ZA, Huggins KN, Sheppard AB, Noel DM, Roane DS, Brown RW (2010) Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood. Synapse 64:289–300PubMedCentralPubMedCrossRefGoogle Scholar
  21. Corrigall WA (1991) Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86:507–510PubMedCrossRefGoogle Scholar
  22. Curzon P, Kim DJ, Decker MW (1994) Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol Biochem Behav 49:877–882PubMedCrossRefGoogle Scholar
  23. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446PubMedCrossRefGoogle Scholar
  24. Elliott BM, Faraday MM, Phillips JM, Grunberg NE (2004) Effects of nicotine on elevated plus maze and locomotor activity in male and female adolescent and adult rats. Pharmacol Biochem Behav 77:21–28PubMedCrossRefGoogle Scholar
  25. Ericson M, Olausson P, Engel JA, Söderpalm B (2000) Nicotine induces disinhibitory behavior in the rat after subchronic peripheral nicotinic acetylcholine receptor blockade. Eur J Pharmacol 397:103–111PubMedCrossRefGoogle Scholar
  26. Faraday MM, Rahman MA, Scheufele PM, Grunberg NE (1998) Nicotine administration impairs sensory gating in Long-Evans rats. Pharmacol Biochem Behav 61:281–289PubMedCrossRefGoogle Scholar
  27. Faraday MM, O’Donoghue VA, Grunberg NE (1999) Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacol Biochem Behav 62:273–284PubMedCrossRefGoogle Scholar
  28. File SE, Kenny PJ, Ouagazzal AM (1998) Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav Neurosci 112:1423–1429PubMedCrossRefGoogle Scholar
  29. File SE, Cheeta S, Kenny PJ (2000) Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 393:231–236PubMedCrossRefGoogle Scholar
  30. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011) Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471:597–601PubMedCentralPubMedCrossRefGoogle Scholar
  31. Fowler CD, Tuesta L, Kenny PJ (2013) Role of alpha5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice. Psychopharmacology 229:503–513Google Scholar
  32. George SA, Moselhy H (2005) “Gateway hypothesis”—a preliminary evaluation of variables predicting non-conformity. Addict Disord Treat 4:39–40CrossRefGoogle Scholar
  33. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612PubMedCrossRefGoogle Scholar
  34. Hien D, Zimberg S, Weisman S, First M, Ackerman S (1997) Dual diagnosis subtypes in urban substance abuse and mental health clinics. Psychiatr Serv 48:1058–1063PubMedCrossRefGoogle Scholar
  35. Irvine EE, Cheeta S, File SE (1999) Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol 10:691–697PubMedCrossRefGoogle Scholar
  36. Irvine EE, Bagnalasta M, Marcon C, Motta C, Tessari M, File SE, Chiamulera C (2000) Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. Psychopharmacology 153:315–320CrossRefGoogle Scholar
  37. Irvine EE, Cheeta S, File SE (2001) Tolerance to nicotine’s effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav 68:319–325PubMedCrossRefGoogle Scholar
  38. Kandel D (1975) Stages in adolescent involvement in drug use. Science 190:912–914PubMedCrossRefGoogle Scholar
  39. Kandel D, Faust R (1975) Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiatry 32:923–932PubMedCrossRefGoogle Scholar
  40. Katz RJ (1982) Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav 16:965–968PubMedCrossRefGoogle Scholar
  41. Kayir H, Goktalay G, Yavuz O, Uzbay TI (2011) Impact of baseline prepulse inhibition on nicotine-induced locomotor sensitization in rats. Behav Brain Res 216:275–280PubMedCrossRefGoogle Scholar
  42. Kelsey JE, Calabro S (2008) Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats. Psychopharmacology 198:461–466PubMedCrossRefGoogle Scholar
  43. Kessler DA, Hass AE, Feiden KL, Lumpkin M, Temple R (1996a) Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. JAMA 276:1826–1831PubMedCrossRefGoogle Scholar
  44. Kessler DA, Witt AM, Barnett PS, Zeller MR, Natanblut SL, Wilkenfeld JP, Lorraine CC, Thompson LJ, Schultz WB (1996b) The food and drug administration’s regulation of tobacco products. N Engl J Med 335:988–994PubMedCrossRefGoogle Scholar
  45. Kupferschmidt DA, Funk D, Erb S, Lê AD (2010) Age-related effects of acute nicotine on behavioural and neuronal measures of anxiety. Behav Brain Res 213:288–292PubMedCrossRefGoogle Scholar
  46. Laviolette SR, van der Kooy D (2004) The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5:55–65PubMedCrossRefGoogle Scholar
  47. Le AD, Li Z, Funk D, Shram M, Li TK, Shaham Y (2006) Increased vulnerability to nicotine self-administration and relapse in alcohol-naive offspring of rats selectively bred for high alcohol intake. J Neurosci 26:1872–1879PubMedCrossRefGoogle Scholar
  48. Le AD, Lo S, Harding S, Juzytsch W, Marinelli PW, Funk D (2010) Coadministration of intravenous nicotine and oral alcohol in rats. Psychopharmacology 208:475–486PubMedCentralPubMedCrossRefGoogle Scholar
  49. Levine A, Huang Y, Drisaldi B, Griffin EA, Jr., Pollak DD, Xu S, Yin D, Schaffran C, Kandel DB, Kandel ER (2011) Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 3:107ra109Google Scholar
  50. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B (2013) Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the national epidemiologic survey of alcohol and related conditions (NESARC). Am J Addict 22:93–98PubMedCrossRefGoogle Scholar
  51. Lipska BK, Weinberger DR (2002) A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res 4:469–475PubMedCrossRefGoogle Scholar
  52. Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002) Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27:47–54PubMedCrossRefGoogle Scholar
  53. Marshall CE, Dadmarz M, Hofford JM, Gottheil E, Vogel WH (2003) Self-administration of both ethanol and nicotine in rats. Pharmacology 67:143–149PubMedCrossRefGoogle Scholar
  54. Matta SG, Elberger AJ (2007) Combined exposure to nicotine and ethanol throughout full gestation results in enhanced acquisition of nicotine self-administration in young adult rat offspring. Psychopharmacology 193:199–213PubMedCrossRefGoogle Scholar
  55. Mayet A, Legleye S, Chau N, Falissard B (2011) Transitions between tobacco and cannabis use among adolescents: a multi-state modeling of progression from onset to daily use. Addict Behav 36:1101–1105PubMedCrossRefGoogle Scholar
  56. Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–1169PubMedCentralPubMedCrossRefGoogle Scholar
  57. Olausson P, Akesson P, Petersson A, Engel JA, Söderpalm B (2001) Behavioral and neurochemical consequences of repeated nicotine treatment in the serotonin-depleted rat. Psychopharmacology 155:348–361PubMedCrossRefGoogle Scholar
  58. Panlilio LV, Zanettini C, Barnes C, Solinas M, Goldberg SR (2013) Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology 38:1198–1208PubMedCentralPubMedCrossRefGoogle Scholar
  59. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M (2005) Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100:1518–1525PubMedCrossRefGoogle Scholar
  60. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167PubMedCrossRefGoogle Scholar
  61. Perna MK, Cope ZA, Maple AM, Longacre ID, Correll JA, Brown RW (2008) Nicotine sensitization in adult male and female rats quinpirole-primed as neonates. Psychopharmacology 199:67–75PubMedCrossRefGoogle Scholar
  62. Peters EN, Budney AJ, Carroll KM (2012) Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction 107:1404–1417PubMedCentralPubMedCrossRefGoogle Scholar
  63. Picciotto MR, Corrigall WA (2002) Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 22:3338–3341PubMedGoogle Scholar
  64. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177PubMedCrossRefGoogle Scholar
  65. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, Fratta W (2008) Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 28:12318–12327PubMedCentralPubMedCrossRefGoogle Scholar
  66. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336PubMedGoogle Scholar
  67. Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379–391PubMedCrossRefGoogle Scholar
  68. Redner R, White TJ, Harder VS, Higgins ST (2014) Vulnerability to smokeless tobacco use among those dependent on alcohol or illicit drugs. Nicotine Tob Res 16:216–223PubMedCrossRefGoogle Scholar
  69. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA 264:2511–2518PubMedCrossRefGoogle Scholar
  70. Rodvelt KR, Bumgarner DM, Putnam WC, Miller DK (2007) WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release. Life Sci 80:337–344PubMedCrossRefGoogle Scholar
  71. SAMHSA (2012) Results from the 2012 national survey on drug use and health: summary of national findings, SAMHSA, RockvilleGoogle Scholar
  72. Sams-Dodd F, Lipska BK, Weinberger DR (1997) Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132:303–310PubMedCrossRefGoogle Scholar
  73. Santiago SE, Huffman KJ (2014) Prenatal nicotine exposure increases anxiety and modifies sensorimotor integration behaviors in adult female mice. Neurosci Res 79:41–51PubMedCrossRefGoogle Scholar
  74. Schreiber R, Dalmus M, De Vry J (2002) Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 159:248–257PubMedCrossRefGoogle Scholar
  75. Semba J, Mataki C, Yamada S, Nankai M, Toru M (1998) Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389–391PubMedCrossRefGoogle Scholar
  76. Slawecki CJ, Gilder A, Roth J, Ehlers CL (2003) Increased anxiety-like behavior in adult rats exposed to nicotine as adolescents. Pharmacol Biochem Behav 75:355–361PubMedCrossRefGoogle Scholar
  77. Slawecki CJ, Thorsell A, Ehlers CL (2004) Long-term neurobehavioral effects of alcohol or nicotine exposure in adolescent animal models. Ann NY Acad Sci 1021:448–452PubMedCrossRefGoogle Scholar
  78. Suemaru K, Yasuda K, Cui R, Li B, Umeda K (2006) Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice. Physiol Behav 88:545–549PubMedCrossRefGoogle Scholar
  79. Swendsen J, Conway KP, Degenhardt L, Glantz M, Jin R, Merikangas KR, Sampson N, Kessler RC (2010) Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the national comorbidity survey. Addiction 105:1117–1128PubMedCentralPubMedCrossRefGoogle Scholar
  80. Szabo ST, Fowler JC, Froeliger B, Lee TH (2014) Time-dependent changes in nicotine behavioral responsivity during early withdrawal from chronic cocaine administration and attenuation of cocaine sensitization by mecamylamine. Behav Brain Res 262:42–46PubMedCrossRefGoogle Scholar
  81. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:1029–1032PubMedCrossRefGoogle Scholar
  82. Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark DB (2006) Predictors of marijuana use in adolescents before and after licit drug use: examination of the gateway hypothesis. Am J psychiatry 163:2134–2140PubMedCrossRefGoogle Scholar
  83. Timberlake DS, Haberstick BC, Hopfer CJ, Bricker J, Sakai JT, Lessem JM, Hewitt JK (2007) Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents. Drug Alcohol Depend 88:272–281PubMedCrossRefGoogle Scholar
  84. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E, Janowsky DS, Kling MA (1999) Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142:193–199PubMedCrossRefGoogle Scholar
  85. Tizabi Y, Getachew B, Rezvani AH, Hauser SR, Overstreet DH (2009) Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 33:398–402PubMedCentralPubMedCrossRefGoogle Scholar
  86. Tizabi Y, Hauser SR, Tyler KY, Getachew B, Madani R, Sharma Y, Manaye KF (2010) Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats. Prog Neuropsychopharmacol Biol Psychiatry 34:62–69PubMedCentralPubMedCrossRefGoogle Scholar
  87. Tullis LM, Dupont R, Frost-Pineda K, Gold MS (2003) Marijuana and tobacco: a major connection? J Addict Dis 22:51–62PubMedCrossRefGoogle Scholar
  88. Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA (2012) Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective. Drug Alcohol Depend 123:S3–S17Google Scholar
  89. Varani AP, Moutinho LM, Bettler B, Balerio GN (2012) Acute behavioural responses to nicotine and nicotine withdrawal syndrome are modified in GABA(B1) knockout mice. Neuropharmacology 63:863–872PubMedCrossRefGoogle Scholar
  90. Vaughn M, Wallace J, Perron B, Copeland V, Howard M (2008) Does marijuana use serve as a gateway to cigarette use for high-risk African-American youth? Am J Drug Alcohol Abuse 34:782–791PubMedCentralPubMedCrossRefGoogle Scholar
  91. Vázquez-Palacios G, Bonilla-Jaime H, Velázquez-Moctezuma J (2004) Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine [correction of flouxetine]. Pharmacol Biochem Behav 78:165–169PubMedCrossRefGoogle Scholar
  92. Vázquez-Palacios G, Bonilla-Jaime H, Velázquez-Moctezuma J (2005) Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. Prog Neuropsychopharmacol Biol Psychiatry 29:39–46PubMedCrossRefGoogle Scholar
  93. Vieyra-Reyes P, Mineur YS, Picciotto MR, Túnez I, Vidaltamayo R, Drucker-Colín R (2008) Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. Brain Res Bull 77:13–18PubMedCentralPubMedCrossRefGoogle Scholar
  94. Villégier A-S, Gallager B, Heston J, Belluzzi JD, Leslie FM (2010) Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats. Psychopharmacology 208:593–601PubMedCentralPubMedCrossRefGoogle Scholar
  95. Wang T, Han W, Wang B, Jiang Q, Solberg-Woods LC, Palmer AA, Chen H (2014) Propensity for social interaction predicts nicotine-reinforced behaviors in outbred rats. Genes Brain Behav 13:202–212PubMedCrossRefGoogle Scholar
  96. Watkins SS, Koob GF, Markou A (2000) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19–37PubMedCrossRefGoogle Scholar
  97. Weiss S, Nosten-Bertrand M, McIntosh JM, Giros B, Martres MP (2007) Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 32:2465–2478PubMedCrossRefGoogle Scholar
  98. Yamaguchi K, Kandel DB (1984) Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health 74:668–672PubMedCentralPubMedCrossRefGoogle Scholar
  99. Zarrindast MR, Aghamohammadi-Sereshki A, Rezayof A, Rostami P (2012) Nicotine-induced anxiogenic-like behaviours of rats in the elevated plus-maze: possible role of NMDA receptors of the central amygdala. J Psychopharmacol 26:555–563PubMedCrossRefGoogle Scholar
  100. Zickler P (2000) Nicotine craving and heavy smoking may contribute to increased use of cocaine and heroin. NIDA Notes 15Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Translational Addiction Research LaboratoryCentre for Addiction and Mental HealthTorontoCanada
  2. 2.Ambulatory Care and Structured Treatment ProgramCentre for Addiction and Mental HealthTorontoCanada
  3. 3.Departments of Family and Community Medicine, Pharmacology, PsychiatryInstitute of Medical Sciences, University of TorontoTorontoCanada
  4. 4.Lunenfeld Tanenbaum Research InstituteMount Sinai HospitalTorontoCanada
  5. 5.Centre for Addiction and Mental HealthTorontoCanada

Personalised recommendations